

Summary Public Assessment Report

Ticagrelor SUN (ticagrelor)

SE/H/2461/001-002/DC

Summary Public Assessment Report

Ticagrelor SUN
ticagrelor

Film-coated tablet, 60 mg, 90 mg

This is a summary of the public assessment report (PAR) for Ticagrelor SUN. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Ticagrelor SUN and what is it used for?

The product is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Brilique.

This product belongs to a group of medicines called antiplatelet medicines. It is used in combination with acetylsalicylic acid (another antiplatelet agent) and is to be used in adults only. The product is used in the treatment of reducing the chances of you having another heart attack, stroke or dying from a disease related to your heart or blood vessels.

The product can be used by patients who you have had:

- a heart attack, over a year ago. *[60 mg, 90 mg]*
- unstable angina (angina or chest pain that is not well controlled). *[90 mg]*

How does Ticagrelor SUN work?

This product affects cells called 'platelets' (also called thrombocytes). These very small blood cells help stop bleeding by clumping together to plug tiny holes in blood vessels that are cut or damaged. platelets can also form clots inside diseased blood vessels in the heart and brain. This can be very dangerous because:

- the clot can cut off the blood supply completely; this can cause a heart attack (myocardial infarction) or stroke, or
- the clot can partly block the blood vessels to the heart; this reduces the blood flow to the heart and can cause chest pain which comes and goes (called 'unstable angina').

This product helps stop the clumping of platelets. This reduces the chance of a blood clot forming that can reduce blood flow.

How is Ticagrelor SUN used?

The pharmaceutical form is film-coated tablet for oral use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Ticagrelor SUN have been shown in studies?

Because the product is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Brilique. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects from Ticagrelor SUN?

Because the product is a generic medicine, its benefits and possible side effects are taken as being the same as the reference medicine.

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Ticagrelor SUN approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Brilique, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Ticagrelor SUN?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Ticagrelor SUN

The full PAR for Ticagrelor SUN can be found on the following website: [MRI - Home](#). For more information about treatment with Ticagrelor SUN, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2025-01.